Coronation Fund Managers Ltd. Has $2.11 Million Holdings in Danaher Corporation $DHR

Key Points

• Coronation Fund Managers Ltd. cut its Danaher position by 52.5% in the first quarter, leaving it with 11,118 shares worth about $2.11 million.
• Danaher’s latest quarterly results beat estimates, with EPS of $1.94 on revenue of about $6.26 billion, and the company raised full-year adjusted EPS guidance.
• Despite the earnings beat, shares fell after Danaher cut its 2026 core revenue growth outlook and gave softer Q3 guidance, with weak bioprocessing results cited as a key concern.

Coronation Fund Managers Ltd. reduced its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 52.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,118 shares of the conglomerate's stock after selling 12,278 shares during the period. Coronation Fund Managers Ltd.'s holdings in Danaher were worth $2,108,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Main Street Group LTD acquired a new position in shares of Danaher in the first quarter valued at $25,000. JPL Wealth Management LLC acquired a new stake in shares of Danaher during the 3rd quarter worth approximately $25,000. Elevated Capital Advisors LLC acquired a new stake in shares of Danaher during the 4th quarter worth approximately $26,000. WFA of San Diego LLC bought a new stake in Danaher in the second quarter valued at about $26,000. Finally, Hilton Head Capital Partners LLC bought a new stake in Danaher in the fourth quarter valued at approximately $27,000. Institutional investors own 79.05% of the company's stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher beat Q2 estimates, with adjusted EPS of $1.94 and revenue of about $6.27 billion, while also raising its full-year adjusted EPS guidance. Danaher Reports Second Quarter 2026 Results
• Positive Sentiment: Some commentary suggests the selloff may be overdone, with technical traders pointing to possible capitulation and bullish buying interest. Stock Of The Day: Is The Danaher Selloff Over?
• Positive Sentiment: Wall Street analysts still see meaningful upside potential, with recent price-target work implying about 32% upside from current levels. Zacks price target article
• Neutral Sentiment: Conference-call coverage highlighted ongoing core momentum, suggesting the long-term business trend is still intact despite the market reaction. Danaher Corp (DHR) Q2 2026 Earnings Call Highlights
• Negative Sentiment: Investors reacted badly to the cut in Danaher’s 2026 core revenue growth outlook and softer Q3 growth guidance, which raised concerns about slower sales momentum. Reuters Danaher outlook cut article
• Negative Sentiment: Weak bioprocessing results were a major disappointment and appear to be the key reason shares fell sharply despite the earnings beat. Danaher Plummets After One Segment Comes In 'Surprisingly Soft'

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Evercore restated an "outperform" rating and issued a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Morgan Stanley dropped their price objective on shares of Danaher from $270.00 to $255.00 and set an "overweight" rating on the stock in a report on Wednesday, April 22nd. Weiss Ratings raised Danaher from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. lowered their price objective on shares of Danaher from $275.00 to $245.00 and set an "overweight" rating on the stock in a report on Wednesday, April 22nd. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $245.00 price objective on shares of Danaher in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $228.91.

Danaher Stock Performance

Shares of NYSE DHR opened at $179.12 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The stock has a 50 day moving average price of $184.49 and a 200 day moving average price of $197.34. The stock has a market capitalization of $126.78 billion, a PE ratio of 31.82, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.06% and a net margin of 15.95%.The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the previous year, the firm earned $0.77 EPS. The business's quarterly revenue was up 5.5% on a year-over-year basis. Analysts predict that Danaher Corporation will post 8.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher's payout ratio is presently 30.95%.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.